Relmada Therapeutics RLMD Institutional Ownership

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is held by 128 institutional investors per 13F filings through June 2026.

• Their combined ownership stood at 90.1% of outstanding shares in June 2026, down from 109.5% in March 2026.
• Their total shares held in RLMD increased 48.95% from the prior quarter, while the number of investors in Relmada Therapeutics increased 156.0% year over year.
• During the quarter, 84 of these 128 funds increased positions in RLMD, 22 reduced exposure, and 22 held steady.
• The aggregate institutional position in Relmada Therapeutics amounted to 101.23Mn shares as of June 2026, up by 33.27Mn shares quarter on quarter, and up 95.73Mn shares year over year.
• Jupiter Topco LLC leads ownership in RLMD with 11.16Mn shares as of June 30, 2026, equal to 9.94% of outstanding shares.
• The largest buyers of Relmada Therapeutics for the quarter ending June 2026 were Jupiter Topco LLC (11.16Mn), BlackRock, Inc. (6.14Mn), Jones Hill Capital LP (3.31Mn), State Street Corp (2.16Mn), Venrock Adviser, LLC (2.0Mn).
• The largest sales of RLMD for the quarter ending June 2026 came from MARSHALL WACE, LLP (2.23Mn), MILLENNIUM MANAGEMENT LLC (1.55Mn), Squadron Capital Management LLC (1.12Mn), ORBIMED ADVISORS LLC (1.08Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (981.46K).
• Business Quant data shows the 10 biggest positions in Relmada Therapeutics as of June 2026 are held by Jupiter Topco LLC (11.16Mn), BlackRock, Inc. (7.43Mn), Squadron Capital Management LLC (7.35Mn), Venrock Adviser, LLC (6.84Mn), Spruce Street Capital LP (6.39Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.76Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.46Mn), Jones Hill Capital LP (3.66Mn), ORBIMED ADVISORS LLC (3.63Mn), State Street Corp (2.52Mn).